---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-052231"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:27:12.049417+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio secures long-term umbilical cord supply for CORDStrom MSC platform via Anthony Nolan agreement

## Summary
- AN granted exclusive license to use donor materials; INmune Bio added as party with joint liability for royalty payments.
- AN receives 2% royalty on net sales of each product, capped at £5M annually; £400+VAT fees per cord tissue, CPI-adjusted annually.
- Term runs until 10 years after first commercial sale; either party may terminate with 30 days (IMB/INMB) or 6 months (AN) notice.
- Pipeline targets RDEB, CORDStrom-col7a, CORDStrom-TRAIL (oncology), osteoarthritis, and systemic lupus erythematosus (SLE).
- Materials handled per GMP and HTA standards; enables global regulatory compliance (FDA, EMA, MHRA).

## SEC filing metadata
- accession: 0001213900-26-052231
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/ea0288685-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-052231
- JSON: https://secwatch.observer/filing/0001213900-26-052231.json
- Plain text: https://secwatch.observer/filing/0001213900-26-052231.txt

## Source-grounded claims
- claim_id: 5b21b6256b459eb05833691031c73ed5ed00b3b4
  claim: Inmune Bio, Inc. entered into Amended and Restated Material Transfer and License Agreement with Anthony Nolan valued at an annual cap of £5,000,000 (effective 2026-04-29).
  evidence_excerpt: On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390026052231/0001213900-26-052231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.